Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with FDA approval for type 2 diabetes (Ozempic injectable, 2017; Rybelsus oral tablet, 2019) and chronic weight management (Wegovy injectable, 2021). It is the most extensively studied peptide on the CheckPeptides directory: over 150 registered clinical trials and more than 4,600 research papers have shaped its regulatory profile. Unlike most peptides in this catalogue, semaglutide is a fully approved pharmaceutical — the questions around it are not whether it works but how to source it, how to tolerate it, and how the 2025-2026 FDA compounding changes affect availability.

Mechanistically, semaglutide mimics native GLP-1, an incretin hormone with a native half-life of about two minutes. Molecular modifications to semaglutide — a fatty acid side chain that binds albumin, and substitutions at positions 8 and 34 that resist DPP-4 degradation — extend its half-life to approximately one week, enabling once-weekly subcutaneous dosing. In the pancreas it binds GLP-1 receptors on beta cells, stimulating glucose-dependent insulin secretion while suppressing glucagon release from alpha cells. The glucose-dependence matters: semaglutide does not cause hypoglycaemia on its own because insulin only rises when blood glucose is already elevated. In the stomach it activates myenteric plexus receptors to slow gastric emptying, which flattens postprandial glucose spikes and prolongs satiety. In the brain it crosses into the hypothalamic arcuate nucleus, suppressing orexigenic NPY/AgRP neurons and stimulating anorexigenic POMC neurons — the central appetite-reduction mechanism that drives the weight loss effect.

Clinical evidence is deep and across populations. The SUSTAIN programme for type 2 diabetes showed HbA1c reductions of 1.0-1.8% and 5-10% weight loss across multiple comparator arms. The STEP obesity programme — the pivotal data for Wegovy — demonstrated 15-20% average body weight loss at 2.4 mg weekly over 68 weeks with lifestyle intervention. The SELECT cardiovascular outcomes trial, published in 2023 with follow-up through 2024, showed a 20% reduction in major adverse cardiovascular events (MI, stroke, cardiovascular death) in overweight/obese patients with established cardiovascular disease, independent of diabetes status — the first weight-loss drug to demonstrate primary cardiovascular benefit. Real-world 2025 data broadly confirm trial efficacy, with a tighter distribution for brand-name injectable and wider variability for compounded formulations.

The 2024-2026 compounding situation is worth understanding because it changes access materially. During the FDA-declared shortage (2022-2024), 503A and 503B compounding pharmacies were permitted to produce semaglutide at scale to meet demand. The FDA declared the shortage resolved in early 2025, which ended the enforcement discretion that had allowed mass compounding. As of 2026, only 503B outsourcing facilities producing under CGMP, for specific clinical need (allergies, personalised dosing), can legally compound semaglutide — and only with a valid prescription. Non-pharmacy "research-grade" semaglutide sold as a research chemical remains outside the legal consumption pathway and carries purity/identity risk that brand-name supply does not.

Typical dosing follows the approved titration. Ozempic for diabetes and cardiovascular risk reduction: 0.25 mg weekly for 4 weeks, then 0.5 mg, with titration up to 1 mg or 2 mg weekly based on response. Wegovy for weight management: 0.25 mg weekly titrated every 4 weeks (0.5 → 1.0 → 1.7 mg) to a maintenance of 2.4 mg weekly. Slower titration reduces the incidence of gastrointestinal side effects. Rybelsus (oral) has roughly 1% bioavailability because of enzymatic degradation in the gut, so dosing runs 3 mg daily for 30 days, then 7 mg, with a maximum of 14 mg daily — taken on an empty stomach with plain water and no food for 30 minutes after. Compounded semaglutide follows the same titration curves but relies on vial-and-syringe dosing rather than prefilled pens.

Safety requires explicit attention. Semaglutide carries an FDA black box warning for thyroid C-cell tumours (medullary thyroid carcinoma, MTC), based on rodent carcinogenicity data; it is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). The most common adverse effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation, affecting 10-20% of users at maintenance doses — and usually attenuate with continued use. Less common but clinically important: acute pancreatitis, cholelithiasis and gallbladder disease (2-4% incidence above baseline), gastroparesis that persists after discontinuation in some cases, and emerging 2024-2025 pharmacovigilance signals for non-arteritic anterior ischaemic optic neuropathy (NAION) with odds ratios in the 2-7x range depending on cohort. The FDA and EMA have also reviewed post-marketing reports of suicidal ideation, with mixed findings — current guidance is monitoring rather than contraindication. Pregnancy should be avoided.

For a consumer deciding between brand-name, 503B compounded, and research-chemical semaglutide in 2026, the relevant trade-offs are price, supply reliability, and risk. Brand-name injectables cost $1,000-1,400/month without insurance, with patient-assistance programmes and post-2024 copay expansions bringing out-of-pocket to $25-100 for many insured patients. 503B compounded runs $200-500/month with prescription, at the cost of more variability in fill and formulation. Research-grade peptides sold as "not for human consumption" sit outside the therapeutic pathway entirely — they are cheaper, but purity is vendor-dependent and legal use is limited to research. Weight regain after discontinuation averages roughly two-thirds of lost weight within a year, which makes the duration-of-use question as important as the initial tolerability question.